FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W69705680> ?p ?o ?g. }

• W69705680 endingPage "236" @default.
• W69705680 startingPage "229" @default.
• W69705680 abstract "Carboplatin/paclitaxel every 3 weeks is the standard for patients with ovarian cancer, but elderly patients frequently receive modified schedules or single agent chemotherapy to avoid toxicity. A phase II study was conducted to describe tolerability of a weekly schedule of both drugs in elderly patients. Patients aged ≥70 years with stage IC-IV ovarian cancer, performance status ≤2, were eligible. Treatment was carboplatin (AUC 2) + paclitaxel (60 mg/m2) on days 1, 8, 15 every 4 weeks, up to six cycles. A two-stage design was applied with lack of unacceptable toxicity as primary endpoint; 26 patients were required at the final stage, with at least 23 of them without unacceptable toxicity to conclude for a positive result. Geriatric assessment was performed by activity daily living (ADL) and instrumental ADL (IADL) scales. Twenty-six patients were analysed (median age 77 years, range 70–84). Performance status was 0 in 10 and 1 in 16 patients; 14 patients had two or more comorbidities; 8 and 18 patients had some dependency in ADL or IADL. Twenty-three patients (88.5%) were treated without suffering unacceptable toxicity. Unacceptable toxic events were grade 3 heart rhythm, grade 3 increase of liver transaminases and prolonged haematological toxicity. Grade 1 neuropathy was reported in four cases. Out of 13 patients evaluable by RECIST, 5 partial responses were observed (response rate 38.5%). Two complete responses were observed among six patients with non-target lesions. Eight patients eligible for CA-125 response assessment had a response after six cycles. Median estimated progression-free survival was 13.6 months, and median overall survival was 32.0 months. In a series of elderly ovarian cancer patients, characterized by a high incidence of comorbidities and functional impairment, weekly carboplatin and paclitaxel demonstrated a favourable toxicity profile." @default.
• W69705680 created "2016-06-24" @default.
• W69705680 creator A5004691735 @default.
• W69705680 creator A5015740152 @default.
• W69705680 creator A5016655393 @default.
• W69705680 creator A5026048739 @default.
• W69705680 creator A5030229940 @default.
• W69705680 creator A5030595144 @default.
• W69705680 creator A5034356923 @default.
• W69705680 creator A5046097436 @default.
• W69705680 creator A5047868780 @default.
• W69705680 creator A5061939825 @default.
• W69705680 creator A5083659627 @default.
• W69705680 date "2008-06-01" @default.
• W69705680 modified "2023-10-14" @default.
• W69705680 title "A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer" @default.
• W69705680 cites W1942713680 @default.
• W69705680 cites W1975536614 @default.
• W69705680 cites W1987437069 @default.
• W69705680 cites W2000437985 @default.
• W69705680 cites W2006318999 @default.
• W69705680 cites W2011662336 @default.
• W69705680 cites W2013095599 @default.
• W69705680 cites W2018499481 @default.
• W69705680 cites W2023117080 @default.
• W69705680 cites W2029409133 @default.
• W69705680 cites W2036206339 @default.
• W69705680 cites W2038191095 @default.
• W69705680 cites W2043481795 @default.
• W69705680 cites W2049333033 @default.
• W69705680 cites W2068714195 @default.
• W69705680 cites W2069760704 @default.
• W69705680 cites W2070887197 @default.
• W69705680 cites W2084460969 @default.
• W69705680 cites W2085370436 @default.
• W69705680 cites W2085811652 @default.
• W69705680 cites W2097105130 @default.
• W69705680 cites W2099847305 @default.
• W69705680 cites W2103799380 @default.
• W69705680 cites W2106181418 @default.
• W69705680 cites W2107243894 @default.
• W69705680 cites W2116996913 @default.
• W69705680 cites W2126277530 @default.
• W69705680 cites W2130941707 @default.
• W69705680 cites W2136753100 @default.
• W69705680 cites W2139248078 @default.
• W69705680 cites W2140949677 @default.
• W69705680 cites W2143219457 @default.
• W69705680 cites W2145911819 @default.
• W69705680 cites W2328421677 @default.
• W69705680 cites W3023720991 @default.
• W69705680 doi "https://doi.org/10.1016/j.critrevonc.2007.12.005" @default.
• W69705680 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18243011" @default.
• W69705680 hasPublicationYear "2008" @default.
• W69705680 type Work @default.
• W69705680 sameAs 69705680 @default.
• W69705680 citedByCount "65" @default.
• W69705680 countsByYear W697056802012 @default.
• W69705680 countsByYear W697056802013 @default.
• W69705680 countsByYear W697056802014 @default.
• W69705680 countsByYear W697056802015 @default.
• W69705680 countsByYear W697056802016 @default.
• W69705680 countsByYear W697056802017 @default.
• W69705680 countsByYear W697056802018 @default.
• W69705680 countsByYear W697056802019 @default.
• W69705680 countsByYear W697056802020 @default.
• W69705680 countsByYear W697056802021 @default.
• W69705680 countsByYear W697056802022 @default.
• W69705680 countsByYear W697056802023 @default.
• W69705680 crossrefType "journal-article" @default.
• W69705680 hasAuthorship W69705680A5004691735 @default.
• W69705680 hasAuthorship W69705680A5015740152 @default.
• W69705680 hasAuthorship W69705680A5016655393 @default.
• W69705680 hasAuthorship W69705680A5026048739 @default.
• W69705680 hasAuthorship W69705680A5030229940 @default.
• W69705680 hasAuthorship W69705680A5030595144 @default.
• W69705680 hasAuthorship W69705680A5034356923 @default.
• W69705680 hasAuthorship W69705680A5046097436 @default.
• W69705680 hasAuthorship W69705680A5047868780 @default.
• W69705680 hasAuthorship W69705680A5061939825 @default.
• W69705680 hasAuthorship W69705680A5083659627 @default.
• W69705680 hasConcept C121608353 @default.
• W69705680 hasConcept C126322002 @default.
• W69705680 hasConcept C141071460 @default.
• W69705680 hasConcept C197934379 @default.
• W69705680 hasConcept C203092338 @default.
• W69705680 hasConcept C2776694085 @default.
• W69705680 hasConcept C2776907518 @default.
• W69705680 hasConcept C2777292972 @default.
• W69705680 hasConcept C2778239845 @default.
• W69705680 hasConcept C2778375690 @default.
• W69705680 hasConcept C2780427987 @default.
• W69705680 hasConcept C2781451048 @default.
• W69705680 hasConcept C29730261 @default.
• W69705680 hasConcept C535046627 @default.
• W69705680 hasConcept C71924100 @default.
• W69705680 hasConceptScore W69705680C121608353 @default.
• W69705680 hasConceptScore W69705680C126322002 @default.

• next